投資涉及風險,包括可能損失本金。投資新興市場涉及其他風險,例如較高的市場波幅及較低的交易成交量,因此可能需要承受比投資成熟市場更易受損失的風險。請於投資前仔細考慮基金的投資目標、風險因素, 以及費用和支出。這些和其他數據記載於有關基金章程內,請於投資前仔細閱覽基金章程。華夏基金並非由指數供應商(只適用於ETF和指數基金)營辦、贊許、發行、銷售或推廣。有關指數供應商的詳情(包括任何免責聲明),請參閱相關華夏基金的發售文件。
資料來源:基金表現和指數數據(如適用)分別由華夏基金和相關指數供應商提供。
本網站由華夏基金(香港)有限公司編制,並未經證券及期貨事務監察委員會審閱。
中證指數免責聲明
滬深300指數("指數")的所有權利歸屬於中證指數有限公司("中證")。"CSI 300®"是中證的註冊商標。中證對於指數相關資料的準確性和完整性不作任何明示或暗示的擔保。中證不因指數的任何錯誤對任何人承擔責任(無論是否存在過失),亦無責任就指數的任何錯誤告知任何人。中證對於跟蹤指數的基金不作任何擔保、背書、銷售或推廣,中證不承擔與此相關的任何責任。
彭博巴克萊指數免責聲明
彭博®是彭博財經有限合夥企業及其關聯方(統稱"彭博")的商標和服務標記。巴克萊®是巴克萊銀行(及其關聯方,統稱"巴克萊")的商標和服務標記,須授權許可方能使用。彭博或彭博的許可人,包括巴克萊,擁有彭博巴克萊指數的所有專屬權利。彭博和巴克萊均非華夏基金(香港)有限公司的關聯方,也沒有批准、背書、評論或推薦華夏彭博巴克萊中國國債+政策性銀行債券指數ETF。彭博和巴克萊不保證任何與彭博巴克萊中國國債及政策性銀行債券指數有關的數據或信息的時效性、準確性或完整性,也不對華夏基金(香港)有限公司、華夏彭博巴克萊中國國債+政策性銀行債券指數ETF的投資者或其它第三方使用彭博巴克萊中國國債+政策性銀行指數或其包含的任何數據或其準確性承擔任何責任。
MSCI指數免責聲明
本基金並非由MSCI保薦、擔保或推介,且就任何此類基金MSCI不承擔任何責任。招股書中包含對MSCI和華夏基金(香港)管理有限公司之間有限關係的更詳細描述。投資涉及風險。投資者應該在投資前細閱發行章程及產品資料概要以便獲得進一步的資料(包括其風險因素)。
NASDAQ 100指數
產品並非由The NASDAQ OMX Group, Inc.或其聯屬人士(The NASDAQ OMX Group, Inc.連同其聯屬人士稱為「NASDAQ OMX」)贊助、認可、銷售或推廣。NASDAQ OMX並無審核產品是否合法或適合,或有關產品的說明及披露資料是否準確或充足。NASDAQ OMX並無就整體投資於證券或特別投資於產品是否可取,或NASDAQ 100指數(「指數」)是否能夠跟蹤整體股票市場表現而向產品股份的擁有人或任何公眾人士作出任何明示或默示的聲明或保證。NASDAQ OMX與產品及華夏基金的唯一關係為許可NASDAQ OMX的若干商標及商號以及由NASDAQ OMX在並無計及華夏基金或產品情況下釐定、編製及計算的指數。NASDAQ OMX在釐定、編製或計算指數時並無義務考慮華夏基金或其聯屬人士或產品股份擁有人的需要。NASDAQ OMX不負責亦未參與釐定產品股份的價格及數額,或發行或出售有關股份的時間,或釐定或計算產品股份轉換為現金的等式。NASDAQ OMX並無有關產品管理、營銷或買賣的義務或責任。
NASDAQ OMX不保證指數或當中所包含任何數據的準確性及╱或計算不受干擾。NASDAQ OMX不對信託代表產品作為被許可人、被許可人的客戶及對手方、產品股份擁有人或任何其他人士或實體因就本文件所述獲許可權利或任何其他用途使用標的指數或當中所包含任何數據取得的結果作出任何明示或默示的保證。NASDAQ OMX不對指數或當中所包含任何數據就特定目的或用途而言的適銷性或適當性作出任何明示或默示的保證並特此明確表示不承擔任何責任。在不影響前述任何一項的情況下,NASDAQ OMX在任何情況下概不對任何直接、間接、特別、懲罰性、間接或任何其他損害(包括利潤損失)承擔任何責任(即使獲通知可能發生有關損害)。彭博巴克萊指數免責聲明彭博®是彭博財經有限合夥企業及其關聯方(統稱"彭博")的商標和服務標記。巴克萊是巴克萊銀行(及其關聯方,統稱"巴克萊")的商標和服務標記,須授權許可方能使用。彭博或彭博的許可人,包括巴克萊,擁有彭博巴克萊指數的所有專屬權利。彭博和巴克萊均非華夏基金(香港)有限公司的關聯方,也沒有批准、背書、評論或推薦華夏彭博巴克萊中國國債+政策性銀行債券指數ETF。彭博和巴克萊不保證任何與彭博巴克萊中國國債及政策性銀行債券指數有關的數據或信息的時效性、準確性或完整性,也不對華夏基金(香港)有限公司、華夏彭博巴克萊中國國債+政策性銀行債券指數ETF的投資者或其它第三方使用彭博巴克萊中國國債+政策性銀行指數或其包含的任何數據或其準確性承擔任何責任。
恒生指數公司免責聲明
恒生指數,恒生港股通小型股指數及恒生科技指數("該指數")由恒生資訊服務有限公司全權擁有,並已授權恒生指數有限公司發佈及編制。恒生指數有限公司及恒生資訊服務有限公司已同意華夏基金(香港)有限公司可就華夏Direxion恒生指數每日槓桿(2x)產品、華夏Direxion恒生指數每日反向(-1x)產品、華夏恒生科技指數ETF及 華夏恒生港股通小型股指數ETF ("該產品")使用及參考該指數,但是,恒生指數有限公司及恒生資訊服務有限公司並不就該指數及其計算或任何與之有關的數據的準確性或完整性,而向任何人士作出保證或聲明或擔保,也不會就該指數提供或默示任何保證、聲明或擔保。恒生指數有限公司及恒生資訊服務有限公司不會因華夏基金(香港)有限公司就該產品使用及/或參考該指數,或恒生指數有限公司在計算該指數時的任何失準、遺漏、失誤或錯誤導致任何人士因上述原因而直接或間接蒙受的任何經濟或其他損失承擔任何責任或債務。任何就該產品進行交易的人士不應依賴恒生指數有限公司及恒生資訊服務有限公司,亦不應以任何形式向恒生指數有限公司及/或恒生資訊服務有限公司進行索償或法律訴訟。為免疑慮,本免責聲明不構成任何經紀或就該產品進行交易的其他人士與恒生指數有限公司及/或恒生資訊服務有限公司之間的任何合約或準合約關係,也不應視作已構成這種關係。
本網站的資料乃由華夏基金(香港)有限公司(簡稱「華夏(香港)」)編制,僅供參閱用途。本網站有關基金的內容不適用於在限制該內容之發佈的區域居住之人士。就任何不獲授權進行分銷或要約的任何司法管轄區,本網站所載資料並不構成任何證券的分銷,買賣的要約,或促使買賣的要約。
本網站所載之基金(簡稱「基金」)已獲證監會認可向香港公眾人士全面銷售;其所載之任何內容亦未經證監會審閱。
本網站所提及的任何內容均不構成對基金的任何股份的投資邀約,也不構成對於任何證券的買賣或進行任何交易的投資建議。在使用本網站所載資料以前,閣下須根據個人狀況,確定任何投資,證券或策略是否合適閣下;如有須要,應諮詢獨立專業意見。
投資涉及風險,基金單位價格可升亦可跌,基金過往業績並不表示將來的回報。基金的價值可能會非常波動,並可能於短時間內大幅下跌,閣下亦可能損失全數投資金額。投資者應參閱有關基金之配售備忘錄,以了解基金詳情及風險因素,特別是投資於中國市場所涉及之風險。本基金可投資於洐生工具或結構性產品;該等投資工具可涉及重大風險,例如交易對手違約風險,有可能引致基金蒙受嚴重損失。
華夏(香港)已盡其所知使本網站所載資料在發佈之時準確 ;但華夏(香港)並不保證有關資料的準確性及完備性。華夏(香港),其聯營公司,董事,高級職員及僱員對此網站所提供的資料的任何相關錯誤或遺漏並不負責。華夏(香港)亦對於因使用此網站內容而引致或引發的任何損失或代價不承擔責任。
與本網頁所載資料有關的所有版權,專利權及其他產權均為華夏(香港)或其聯屬公司所有。在未經華夏(香港)同意下,不得複印,分發或複製本網頁內之任何資料或任何部分。
Product Risk Warning:
Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in below products, investor should refer to the Fund's prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:
Important Information about ChinaAMC Hang Seng Hong Kong Biotech Index ETF
Important Information about ChinaAMC Hang Seng TECH Index ETF
Important Information about ChinaAMC CSI 300 Index ETF
Important Information about ChinaAMC NASDAQ 100 ETF
Important Information about ChinaAMC Asia High Dividend ETF
Important Information about ChinaAMC MSCI Japan Hedged to USD ETF
Important Information about ChinaAMC MSCI Europe Quality Hedged to USD ETF
Important Information about ChinaAMC Hong Kong Banks ETF
Important Information about ChinaAMC MSCI Asia Pacific Real Estate ETF
Important Information about ChinaAMC MSCI China A Inclusion Index ETF
Important information about ChinaAMC Hang Seng Stock Connect Hong Kong SmallCap Index ETF
Important Information about ChinaAMC Asia USD Investment Grade Bond ETF
Important Information about ChinaAMC Bloomberg China Treasury + Policy Bank Bond Index ETF
Important Information about ChinaAMC NASDAQ-100 Index Daily (2x) Leveraged Product / ChinaAMC Nasdaq-100 Index Daily (-1x) Inverse Product / ChinaAMC Nasdaq-100 Index Daily (-2x) Inverse Product:
Important Information about ChinaAMC CSI 300 Index Daily (2x) Leveraged Product/ChinaAMC CSI 300 Index Daily (-1x) Inverse Product (The product is a synthetic product):
As the world's largest biotech and pharmaceutical market and fundraising centre, the benchmark index in the US has already risen significantly in the past 10 years. Meanwhile, China as the 2nd largest market is catching up fast and has big rooms for growth
Biotechnology has been identified as one of the key development areas according to the 14th Five-Year Plan and "Made in China 2025" development strategy
In 2018, biotech products accounted only for 5.7% of the total pharmaceutical market in China (vs 26.5% in the world). The aging population in China has also accelerated the demand in China's biotech industry.
China's innovative drug market is expected to achieve 95% growth between 2019 and 2023 with 18% cumulative annual growth rate
Hong Kong has become Asia's largest and the world's second largest biotech fundraising centre^. Since the listing reforms by HKEX in 2018 encouraging biotech IPOs, Hong Kong has turned into the core IPO centre of China's biotech industry
High quality biotech companies in China have gathered in
More biotech companies included
in Stock Connect
Biotech involves specialized knowledge and high information barrier. Investing in ETF avoids the difficulty of stock-picking
The results of biotech R&D are hard to predict. Investing in ETF allows diversification of single company's business risk
The objective checking and periodic screening of an index enables a timely reflection of the industry trend
Low minimum investment amount
Since the launch of the Hang Seng Hong Kong-Listed Biotech Index^, the index has achieved 84.1% performance, outperforming the broad-based Hang Seng Index's 83.0% performance in the same period.
Investing involves risk, including possible loss of principal. Investment in emerging market countries may involve heightened risks such as increased volatility and lower trading volume, and may be subject to a greater risk of loss than investment in a developed country. Please carefully consider the Fund's investment objectives, risk factors, and charges and expenses before investing. This and other information can be found in the relevant Fund's prospectus. Please read the prospectus carefully before investing. ChinaAMC Funds are not sponsored, endorsed, issued, sold or promoted by their index providers (only applicable to ETFs and index funds). For details of an index provider including any disclaimer, please refer to the relevant ChinaAMC Fund offering documents.
Source: Fund performance and index data are provided by ChinaAMC and the relevant index providers (if applicable) respectively. This website is prepared by China Asset Management (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission.
Hang Seng Index Disclaimer
The mark and name Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index are proprietary to Hang Seng Data Services Limited ("HSDS") which has licensed its compilation and publication to Hang Seng Indexes Company Limited ("HSIL"). HSIL and HSDS have agreed to the use of, and reference to Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index by China Asset Management (Hong Kong) Limited ("the Issuer") in connection with the ChinaAMC Hong Kong Biotech Index ETF, ChinaAMC Hang Seng TECH Index ETF and ChinaAMC Hang Seng Stock Connect Hong Kong SmallCap Index ETF (the "Product"). However, neither HSIL nor HSDS warrants, represents or guarantees to any person the accuracy or completeness of the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index, its computation or any information related thereto and no warranty, representation or guarantee of any kind whatsoever relating to the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index are given or may be implied. Neither HSIL nor HSDS accepts any responsibility or liability for any economic or other loss which may be directly or indirectly sustained by any person as a result of or in connection with the use of and/or reference to the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index by the Issuer in connection with the Product, or any inaccuracies, omissions or errors of HSIL in computing the Hang Seng Hong Kong-Listed Biotech Index, Hang Seng TECH Index and Hang Seng Stock Connect Hong Kong SmallCap Index. Any person dealing with the Product shall place no reliance whatsoever on HSIL and/or HSDS nor bring any claims or legal proceedings against HSIL and/or HSDS in any manner whatsoever. For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker or other person dealing with the Product and HSIL and/or HSDS and must not be construed to have created such relationship.
NASDAQ 100 Index Disclaimer
The Product(s) is not sponsored, endorsed, sold or promoted by NASDAQ, Inc. or its affiliates (NASDAQ, Inc. with its affiliates, is referred to as "NASDAQ"). NASDAQ has not passed on the legality or suitability of, or the accuracy or adequacy of descriptions and disclosures relating to, the Product. NASDAQ makes no representation or warranty, express or implied, to the owners of shares of the Product or any member of the public regarding the advisability of investing in securities generally or in the Product particularly or the ability of the Index to track general stock market performance. NASDAQ's only relationship to the Product and China Asset Management (Hong Kong) Limited ("ChinaAMC") is in the licensing of certain trademarks and trade names of NASDAQ and of the Index which is determined, composed and calculated by NASDAQ without regard to ChinaAMC or the Product. NASDAQ QMX has no obligation to take the needs of ChinaAMC or its affiliates or the owners of shares of the Product into consideration in determining, composing or calculating the Index. NASDAQ is not responsible for and has not participated in the determination of the prices and amount of shares of the Product, or the timing of the issuance or sale of such shares or in the determination or calculation of the equation by which shares of the Product are to be converted into cash. NASDAQ has no obligation or liability in connection with the administration, marketing or trading of the Product.
NASDAQ does not guarantee the accuracy and/or uninterrupted calculation of the index or any data included therein. Nasdaq makes no warranty, express or implied, as to results to be obtained by the trust on behalf of the product as licensee, licensee's customers and counterparties, owners of the shares of the product, or any other person or entity from the use of the subject index or any data included therein in connection with the rights licensed as described herein or for any other use. NASDAQ makes no express or implied warranties and hereby expressly disclaims all warranties of merchantability or fitness for a particular purpose or use with respect to the index or any data included therein. Without limiting any of the foregoing, in no event shall NASDAQ have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.
CSI Index Disclaimer
All rights in the CSI 300 Index ("Index") vest in China Securities Index Company ("CSI"). "CSI 300®" is a trade mark of CSI. CSI does not make any warranties, express or implied, regarding the accuracy or completeness of any data related to the Index. CSI is not liable to any person for any error of the Index (whether due to negligence or otherwise), nor shall it be under any obligation to advise any person of any error therein. The Fund based on the Index is in no way sponsored, endorsed, sold or promoted by CSI and CSI shall not have any liability with respect thereto.
Bloomberg China Treasury + Policy Bank Bond Index Disclaimer
BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). Bloomberg or Bloomberg's licensors own all proprietary rights in the Bloomberg Indices. Bloomberg is not affiliated with China Asset Management (Hong Kong) Limited, and does not approve, endorse, review or recommend ChinaAMC Bloomberg China Treasury + Policy Bank Bond Index ETF. Bloomberg does not guarantee the timeliness, accurateness or completeness of any data or information relating to Bloomberg China Treasury + Policy Bank Index, and neither shall be liable in any way to the China Asset Management(Hong Kong) Limited, investors in ChinaAMC Bloomberg China Treasury + Policy Bank Bond Index ETF or other third parties in respect of the use or accuracy of the Bloomberg China Treasury + Policy Bank Index or any data included therein.
MSCI Index Disclaimer
The funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such funds or securities or any index on which such funds or securities are based. The Prospectus contains a more detailed description of the limited relationship MSCI has with China Asset Management (Hong Kong) Limited and any related funds.